Fidelity Investments
VIRX

Fidelity Investments’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Fidelity Investments’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8
Closed -$12 – 5564
2023
Q2 		$12 Buy
+8
New +$11 ﹤0.01% 5259
2022
Q4 		– Sell
-474
Closed -$2K – 5624
2022
Q3 		$2K Sell
474
-257
-35% -$1.09K ﹤0.01% 4604
2022
Q2 		$3K Sell
731
-10,495
-93% -$29.9K ﹤0.01% 4503
2022
Q1 		$54K Buy
11,226
+11,215
+101,955% +$33.8K ﹤0.01% 3662
2021
Q4 		$0 Sell
11
-3
-21% -$16 ﹤0.01% 5039
2021
Q3 		$0 Hold
14
– – ﹤0.01% 5153
2021
Q2 		$0 Hold
14
– – ﹤0.01% 4998
2021
Q1 		$0 Buy
+14
New +$146 ﹤0.01% 4631
2016
Q3 		– Sell
-2,732
Closed -$314K – 2703
2016
Q2 		$314K Sell
2,732
-16,868
-86% -$1.87M ﹤0.01% 2589
2016
Q1 		$2.22M Sell
19,600
-4,609
-19% -$699K ﹤0.01% 2362
2015
Q4 		$4.56M Hold
24,209
– – ﹤0.01% 2222
2015
Q3 		$4.12M Hold
24,209
– – ﹤0.01% 2228
2015
Q2 		$15.3M Hold
24,209
– – ﹤0.01% 1846
2015
Q1 		$12.5M Hold
24,209
– – ﹤0.01% 1917
2014
Q4 		$13M Sell
24,209
-18,381
-43% -$8.28M ﹤0.01% 1913
2014
Q3 		$63.9M Buy
42,590
+4,292
+11% +$6.21M 0.01% 1183
2014
Q2 		$52.4M Sell
38,298
-2,233
-6% -$2.59M 0.01% 1320
2014
Q1 		$56.3M Buy
40,531
+15,916
+65% +$18.5M 0.01% 1267
2013
Q4 		$24.5M Sell
24,615
-3,922
-14% -$4.06M ﹤0.01% 1622
2013
Q3 		$29.7M Sell
28,537
-88
-0.3% -$94K ﹤0.01% 1534
2013
Q2 		$31.3M Buy
+28,625
New +$31.9M 0.01% 1463

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments's VIRX Position: Q3 2023 in Review

Fidelity Investments sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2023, closing a stake of 8 shares — an estimated $12 sold.

Fidelity Investments first reported a position in VIRX in Q2 2013 and held it in 21 quarters. The position peaked at $63.9M in Q3 2014. 42 funds tracked by Wall St. Rank hold VIRX as of Q3 2023.

  • Fidelity Investments reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Fidelity Investments sold 8 Viracta Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $12.
  • Fidelity Investments first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 21 quarters.
  • Fidelity Investments's Viracta Therapeutics, Inc. Common Stock position peaked at $63.9M in Q3 2014.
  • 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.